DeepCyte, a techbio company building AI toxicology tools for drug development, launched today with $1.5 million in seed funding. The company is introducing two solutions to help biopharma teams detect ...
An examination of patient outcomes from the ZUMA-2 trial creates new questions about treatment sequencing. An fresh look at trial results that propelled the only FDA approval of a chimeric antigen ...
Mars may be hostile, but it might not be entirely unlivable. In lab experiments, yeast cells survived simulated Martian shock ...
An antibody treatment developed at Stanford Medicine successfully prepared patients for stem cell transplants without toxic busulfan chemotherapy or radiation, a phase 1 clinical trial has shown.
Graphene oxide (orange) can effectively enter yeast cells and reduce the toxicity of harmful protein aggregates (light grey), by promoting disassembly and then degradation of the aggregates.
Neoadjuvant FOLF(IRIN)OX Chemotherapy for Resectable Pancreatic Adenocarcinoma: A Multicenter Randomized Noncomparative Phase II Trial (PANACHE01 FRENCH08 PRODIGE48 study) Patients were recruited from ...
Phase I clinical trial results suggest that an antibody treatment, used in combination with other drugs, enabled stem cell transplants for three children with Fanconi anemia without toxic busulfan ...
A new study has identified specific cellular machinery that helps brain cells dispose of toxic proteins associated with Alzheimer’s disease. By screening thousands of genes in lab-grown human neurons, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results